Predicting response to anti-CD20 therapy in DLBCL patients
US8592156B2 · kind B2 · utility
15Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 8, 2011 |
| Grant date | Nov 26, 2013 |
| Priority date | — |
| Expiry date | Oct 6, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.